Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CRISPR-SELECT

Financiado

Cerrado

Harnessing a novel CRISPR nuclease for programmable counterselection in human ce...

Harnessing a novel CRISPR nuclease for programmable counterselection in human cells CRISPR technologies have revolutionized genome editing in medicine, agriculture, biotechnology, and life-sciences research with their ability to generate virtually any DNA edit at any genomic site in any organism. However, editing... ver más

30/09/2025

HZI

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

HELMHOLTZZENTRUM FUR INFEKTIONSFORSCHUNG GMBH No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-02-06

ERC-2023-POC: ERC PROOF OF CONCEPT GRANTS Objective:Objectives:The ERC Proof of Concept Grants aim at facilitating exploration of the commerci...

I+D

Cerrada hace 2 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

HZI

150.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

CRISPR2.0 Microbial genome defence pathways from molecular mechanisms... 2M€ Cerrado

CRISPAIR Study of the interplay between CRISPR interference and DNA r... 1M€ Cerrado

GenDels Development of a new CRISPR Cas3 based tool for large genomi... 265K€ Cerrado

CRISPRsition Developing CRISPR adaptation platforms for basic and applied... 2M€ Cerrado

BIO2011-24417 CARACTERIZACION DEL SISTEMA CRISPR/CAS-Y DE ESCHERICHIA COLI 109K€ Cerrado

dCas9 Dissection of the mammalian transcription termination mechan... 183K€ Cerrado

Duración del proyecto: 19 meses Fecha Inicio: 2024-02-06
Fecha Fin: 2025-09-30

Líder del proyecto

HELMHOLTZZENTRUM FUR INFEKTIONSFORSCHUNG GMBH No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto CRISPR technologies have revolutionized genome editing in medicine, agriculture, biotechnology, and life-sciences research with their ability to generate virtually any DNA edit at any genomic site in any organism. However, editing frequencies can be restrictively low, requiring extensive screening to identify cells harboring desired edits. What remains elusive is a way to greatly boost the frequency of editing. While characterizing CRISPR-Cas systems, bacterial defense systems and the source of CRISPR technologies, we discovered a new mechanism that could kill unedited cells yet spare edited cells, regardless of the type of gene edit. This versatile and sequence-specific approach can be described as programmable counter-selection, as undesired cells are targeted for removal, and those cells can be targeted in a programmable way. If proven, this capability could radically boost the effective editing frequencies by removing unedited cells regardless of the underlying edit, providing much-needed relief to the burden of screening imposed on diverse genome-editing applications. Here, we propose to perform proof-of-concept experiments demonstrating this capability in human cells while exploring which editing applications would best benefit from this capability. The associated tasks build on my extensive work at the interface of CRISPR biology and technologies and leverages his numerous academic and industrial contacts. I ultimately aim to translate a novel biological insight from my group’s ERC Consolidator project into an innovative foundational technology, with a clear path toward its broad use in genome editing.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores